Sio Gene Therapies Inc. SIOX
We take great care to ensure that the data presented and summarized in this overview for Sio Gene Therapies Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SIOX
Top Purchases
Top Sells
About SIOX
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Insider Transactions at SIOX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2021
|
Pavan Cheruvu Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,884
-6.83%
|
$14,884
$1.42 P/Share
|
|
Dec 08
2021
|
Pavan Cheruvu Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,567
+14.7%
|
-
|
|
Dec 08
2021
|
David W. Nassif Interim CEO, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,294
-12.21%
|
$6,294
$1.42 P/Share
|
|
Dec 08
2021
|
David W. Nassif Interim CEO, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
17,534
+25.39%
|
-
|
|
Mar 23
2021
|
Pavan Cheruvu Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+35.66%
|
$200,000
$2.48 P/Share
|
|
Mar 22
2021
|
David W. Nassif Interim CEO, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,060
+30.69%
|
-
|
|
Mar 17
2021
|
Pavan Cheruvu Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,590
+21.93%
|
-
|
|
Mar 17
2021
|
Gavin Corcoran Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,001
+38.29%
|
-
|
|
Nov 24
2020
|
Atul Pande Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+23.06%
|
$20,000
$2.34 P/Share
|
|
Mar 18
2019
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,666,667
+5.92%
|
$6,666,667
$1.5 P/Share
|
|
Dec 18
2018
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000,000
+9.15%
|
$10,000,000
$1.0 P/Share
|
|
Jun 05
2018
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
14,285,714
+13.79%
|
$14,285,714
$1.75 P/Share
|